FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2317028051> ?p ?o ?g. }

• W2317028051 endingPage "A61" @default.
• W2317028051 startingPage "A60.3" @default.
• W2317028051 abstract "<h3>Background</h3> Sunitinib and pazopanib are tyrosine kinase inhibitors used in the treatment of metastatic renal cancer. Pazopanib has been approved more recently, so the user experience is not as extensive as with sunitinib. <h3>Purpose</h3> To evaluate the safety profile of pazopanib and sunitinib in patients with metastatic renal cancer. To compare the incidence of adverse reactions between the two drugs. <h3>Materials and Methods</h3> We identified patients treated with sunitinib and pazopanib at the hospital in the past two years, using the pharmacy database. We looked at the medical records of patients through digital medical records, collecting dose patterns, line of therapy, adverse reactions detected, their severity and if dose reductions were necessary, using Excel. <h3>Results</h3> A total of 26 patients with metastatic renal cancer were identified: 16 treated with sunitinib and 10 with pazopanib. Asthenia was the most frequent drug-related toxic effect in both treatment groups, with an incidence of 93.75% for sunitinib and 60% for pazopanib. Nausea/vomiting and diarrhoea were detected in 50% of patients treated with pazopanib. In sunitinib patients nausea/vomiting were detected in 6.25% of patients and diarrhoea was detected in 68.75% of patients For patients who received pazopanib, the rate of mucositis was 20%, whereas for those treated with sunitinib it was 75%. Palmar-plantar erythrodysaesthesia syndrome occurred in 43.75% of those on sunitinib treatment, while none was detected for pazopanib, and the frequency of other skin pigmentation disorders for the two drugs was 62.5% and 30% respectively. Blood pressure was decompensated in 37.5% of patients treated with sunitinib and 10% of those taking pazopanib, although most patients required antihypertensive drugs to get better control. Dose adjustment was required of sunitinib in 43.75% of cases and in 25% pazopanib. <h3>Conclusions </h3> Pazopanib may be better tolerated than sunitinib, with an acceptable adverse event profile and fewer dose adjustments. Also, the severity of adverse events looks lower with pazopanib. However, the number of patients was too small to arrive at definitive conclusions, so it is necessary to enlarge this study. No conflict of interest." @default.
• W2317028051 created "2016-06-24" @default.
• W2317028051 creator A5004956026 @default.
• W2317028051 creator A5005444342 @default.
• W2317028051 creator A5008981986 @default.
• W2317028051 creator A5027394108 @default.
• W2317028051 creator A5043894674 @default.
• W2317028051 creator A5075272412 @default.
• W2317028051 creator A5088718362 @default.
• W2317028051 date "2013-03-01" @default.
• W2317028051 modified "2023-10-16" @default.
• W2317028051 title "GRP-168 Safety of Sunitinib Versus Pazopanib in Metastatic Renal Cancer in a Tertiary Hospital" @default.
• W2317028051 doi "https://doi.org/10.1136/ejhpharm-2013-000276.168" @default.
• W2317028051 hasPublicationYear "2013" @default.
• W2317028051 type Work @default.
• W2317028051 sameAs 2317028051 @default.
• W2317028051 citedByCount "0" @default.
• W2317028051 crossrefType "journal-article" @default.
• W2317028051 hasAuthorship W2317028051A5004956026 @default.
• W2317028051 hasAuthorship W2317028051A5005444342 @default.
• W2317028051 hasAuthorship W2317028051A5008981986 @default.
• W2317028051 hasAuthorship W2317028051A5027394108 @default.
• W2317028051 hasAuthorship W2317028051A5043894674 @default.
• W2317028051 hasAuthorship W2317028051A5075272412 @default.
• W2317028051 hasAuthorship W2317028051A5088718362 @default.
• W2317028051 hasBestOaLocation W23170280511 @default.
• W2317028051 hasConcept C121608353 @default.
• W2317028051 hasConcept C126322002 @default.
• W2317028051 hasConcept C143998085 @default.
• W2317028051 hasConcept C197934379 @default.
• W2317028051 hasConcept C2778375690 @default.
• W2317028051 hasConcept C2778439243 @default.
• W2317028051 hasConcept C2778820342 @default.
• W2317028051 hasConcept C2779490328 @default.
• W2317028051 hasConcept C2780580376 @default.
• W2317028051 hasConcept C2780852908 @default.
• W2317028051 hasConcept C71924100 @default.
• W2317028051 hasConcept C98274493 @default.
• W2317028051 hasConceptScore W2317028051C121608353 @default.
• W2317028051 hasConceptScore W2317028051C126322002 @default.
• W2317028051 hasConceptScore W2317028051C143998085 @default.
• W2317028051 hasConceptScore W2317028051C197934379 @default.
• W2317028051 hasConceptScore W2317028051C2778375690 @default.
• W2317028051 hasConceptScore W2317028051C2778439243 @default.
• W2317028051 hasConceptScore W2317028051C2778820342 @default.
• W2317028051 hasConceptScore W2317028051C2779490328 @default.
• W2317028051 hasConceptScore W2317028051C2780580376 @default.
• W2317028051 hasConceptScore W2317028051C2780852908 @default.
• W2317028051 hasConceptScore W2317028051C71924100 @default.
• W2317028051 hasConceptScore W2317028051C98274493 @default.
• W2317028051 hasIssue "Suppl 1" @default.
• W2317028051 hasLocation W23170280511 @default.
• W2317028051 hasOpenAccess W2317028051 @default.
• W2317028051 hasPrimaryLocation W23170280511 @default.
• W2317028051 hasRelatedWork W2081703574 @default.
• W2317028051 hasRelatedWork W2130046666 @default.
• W2317028051 hasRelatedWork W2156337883 @default.
• W2317028051 hasRelatedWork W2372442000 @default.
• W2317028051 hasRelatedWork W2394317912 @default.
• W2317028051 hasRelatedWork W2883745811 @default.
• W2317028051 hasRelatedWork W2991525471 @default.
• W2317028051 hasRelatedWork W3163179811 @default.
• W2317028051 hasRelatedWork W32471882 @default.
• W2317028051 hasRelatedWork W53594158 @default.
• W2317028051 hasVolume "20" @default.
• W2317028051 isParatext "false" @default.
• W2317028051 isRetracted "false" @default.
• W2317028051 magId "2317028051" @default.
• W2317028051 workType "article" @default.